{ "schemaVersion": 2, "eyebrow": "Vascular Medicine", "title": "Superficial Thrombophlebitis", "summary": "Manage superficial venous thrombosis by defining thrombus extent and deep-system proximity with duplex ultrasound, excluding concurrent DVT, and reserving anticoagulation for disease with meaningful risk of extension or embolization.", "seoDescription": "Physician guide to superficial thrombophlebitis: duplex ultrasound, DVT exclusion, anticoagulation thresholds, fondaparinux dosing, and escalation.", "clinicalQuestion": "How should clinicians evaluate and treat lower-extremity superficial venous thrombosis while preventing DVT and pulmonary embolism?", "specialty": "Vascular Medicine", "audience": "U.S. physicians and medical trainees", "tags": [ "superficial venous thrombosis", "superficial thrombophlebitis", "fondaparinux", "duplex ultrasound", "saphenofemoral junction", "venous thromboembolism" ], "keyTakeaways": [ "Obtain compression/duplex ultrasonography in superficial venous thrombosis to define thrombus length, identify proximity to the deep venous system, and evaluate for concurrent DVT. [14][17]", "Treat lower-extremity SVT with higher risk of progression—especially length at least 5 cm, proximal disease, severe symptoms, great saphenous involvement, prior VTE/SVT, active cancer, recent surgery, pregnancy, or hormonal exposure—with anticoagulation rather than symptomatic therapy alone. [14][16]", "Fondaparinux 2.5 mg subcutaneously once daily for 45 days is the best-supported regimen for eligible higher-risk SVT; rivaroxaban 10 mg once daily had similar efficacy outcomes in a trial comparison. [9][16]", "SVT within 3 cm of the saphenofemoral junction or involving perforators near the popliteal fossa has elevated risk of deep-system extension and warrants urgent anticoagulation-focused management. [16]", "For limited below-knee SVT without DVT, NSAIDs and compression are reasonable symptom-directed management; reassess promptly for worsening symptoms or extension. [1]" ], "sections": [ { "id": "initial-triage-and-ultrasound", "eyebrow": "First Decision", "heading": "Which patients need urgent venous imaging?", "intro": "Do not rely on the visible erythematous cord to establish thrombus extent or exclude DVT.", "paragraphs": [ "Order compression venous ultrasonography for lower-extremity SVT at presentation. Image the symptomatic superficial vein to document thrombus location and extent, and examine the deep venous system; bilateral compression ultrasonography is recommended to detect concomitant venous thromboembolic disease. [14][17] Ultrasound findings supporting SVT include a noncompressible superficial vein, intraluminal thrombus, and absent color Doppler flow; soft-tissue edema and vein-wall thickening may accompany the thrombus. [6][8]", "Treat dyspnea, pleuritic chest pain, syncope, hypoxemia, or hemodynamic instability as possible PE rather than uncomplicated SVT. Concurrent DVT is particularly consequential when thrombus reaches the saphenofemoral junction: 11% to 40% of patients with SVT at that junction have reported concurrent DVT. [7][9] A confirmed DVT changes management from isolated-SVT treatment to therapeutic anticoagulation for venous thromboembolism.", "Document three features from the ultrasound report before selecting therapy: thrombus length, involved vein, and distance to the saphenofemoral or saphenopopliteal junction. Clinical erythema can underestimate thrombus extent, particularly when disease approaches a deep-venous junction. [8]" ], "bullets": [ "Request ultrasound assessment of superficial thrombus length and proximal endpoint, including its relationship to the saphenofemoral and saphenopopliteal junctions. [1][8]", "If DVT is identified, manage as DVT rather than as isolated SVT. [14][17]", "If initial management is non-anticoagulant, arrange reassessment for progression of pain, erythema, or proximal cord extension; propagation despite medical treatment is an indication for vascular escalation. [1]" ], "subsections": [], "table": { "caption": "Ultrasound findings that change the management pathway in superficial venous thrombosis. [1][14][16][17]", "columns": [ "Ultrasound result", "Clinical interpretation", "Next action" ], "rows": [ [ "Concurrent DVT", "Venous thromboembolism is already present. [14][17]", "Use a DVT-directed therapeutic anticoagulation strategy." ], [ "SVT within 3 cm of the saphenofemoral junction or near popliteal perforators", "High risk for propagation into the deep venous system. [16]", "Institute anticoagulation-focused management urgently; involve vascular or thrombosis expertise when anatomy or treatment intensity is uncertain. [1][16]" ], [ "SVT at least 5 cm, proximal to knee, or involving great saphenous vein", "Features associated with higher extension or VTE risk. [14][16]", "Offer anticoagulation if bleeding risk is acceptable. [14][16]" ], [ "Limited below-knee SVT without DVT or high-risk features", "Lower-risk isolated disease. [1][14]", "Use NSAID and compression-based symptomatic management with clinical follow-up. [1]" ] ] } }, { "id": "risk-stratification", "eyebrow": "Extension Risk", "heading": "How to separate low-risk from anticoagulation-eligible SVT", "intro": "Anatomic proximity and patient-level thrombotic risk should both determine treatment intensity.", "paragraphs": [ "Anticoagulation is generally favored for lower-extremity SVT at least 5 cm in length, disease proximal to the knee, severe symptoms, great saphenous involvement, prior SVT or VTE, active malignancy, or recent surgery. [14] Additional progression-risk features include pregnancy, hormonal exposure, and active inflammatory disease. [16] These factors should move management away from NSAID-only treatment even when no DVT is found initially.", "An SVT endpoint less than 3 cm from the saphenofemoral junction is a high-risk anatomic pattern. [16] BMJ guidance similarly identifies thrombus near the saphenofemoral or saphenopopliteal junction as an indication to consider anticoagulation or surgical ligation. [1] Do not classify this anatomy as routine isolated distal SVT.", "Varicose veins support a local venous cause, but their presence does not eliminate thromboembolic risk. In patients with SVT at the saphenofemoral junction, concurrent DVT has been reported less often with varicose veins than without them, 20% versus 60% in cited data. [7][9] Therefore, absence of varicosities should heighten attention to concurrent VTE and systemic provoking factors rather than reassure." ], "bullets": [ "Ask about previous VTE or SVT, active cancer, recent surgery, pregnancy, exogenous hormones, and inflammatory disease because each increases progression risk. [14][16]", "Map whether symptoms and ultrasound involve the great saphenous vein or a thrombus endpoint near a deep-vein junction. [14][16]", "Use bleeding risk and patient preferences to individualize anticoagulation when SVT is anatomically lower risk but patient-level VTE risk is substantial. [16]" ], "subsections": [], "table": null }, { "id": "anticoagulant-treatment", "eyebrow": "Definitive Therapy", "heading": "Anticoagulation regimens for higher-risk isolated SVT", "intro": "Use an anticoagulant regimen with evidence for preventing extension and venous thromboembolism.", "paragraphs": [ "For anticoagulation-eligible isolated lower-extremity SVT, use fondaparinux 2.5 mg subcutaneously once daily for 45 days when not contraindicated. [14][16] Fondaparinux reduced symptomatic VTE compared with placebo in randomized evidence and also reduces extension or recurrence. [5][16] This regimen is particularly applicable to symptomatic above-knee SVT not involving the saphenofemoral junction. [9]", "Rivaroxaban 10 mg orally once daily was noninferior to fondaparinux in the SURPRISE trial population with SVT plus additional risk factors, and a comparison summarized by ASH found no difference in symptomatic VTE or SVT extension between rivaroxaban 10 mg daily and fondaparinux 2.5 mg daily. [3][16] Consider rivaroxaban when an oral regimen is preferred and patient-specific renal function, drug interactions, bleeding risk, and labeled use are suitable; evidence for this approach in SVT is less extensive than for fondaparinux. [16]", "LMWH at prophylactic doses for 30 days is an alternative described by NICE, but that indication is off-label. [20] Evidence synthesis indicates that LMWH reduces SVT extension, whereas only fondaparinux reduced symptomatic VTE versus placebo in the summarized trials. [16] Therefore, choose LMWH chiefly when fondaparinux is unsuitable and a parenteral alternative is needed.", "Do not substitute topical therapies, compression, or surgery for anticoagulation when the purpose is prevention of DVT or PE in higher-risk SVT. Topical treatments improve local symptoms but have inadequate data for VTE or SVT-extension outcomes; surgical evidence is limited and insufficient to guide routine thrombotic-risk management. [17]" ], "bullets": [ "Fondaparinux: 2.5 mg subcutaneously once daily for 45 days for anticoagulation-eligible lower-extremity SVT. [14][16]", "Rivaroxaban: 10 mg orally once daily is supported by comparative trial evidence in SVT with additional risk factors. [3][16]", "LMWH: prophylactic dosing for 30 days is an off-label alternative. [20]", "Escalate rather than continue conservative therapy if thrombus propagates or symptoms persist despite medical treatment; surgical ligation may be considered in selected junctional disease. [1]" ], "subsections": [ { "heading": "Managing thrombus near a deep-venous junction", "paragraphs": [ "For SVT near the saphenofemoral or saphenopopliteal junction, obtain prompt expert input when the appropriate anticoagulant intensity, duration, or role of operative ligation is unclear. Surgical ligation is a consideration for junctional thrombosis, while surgery is also considered for persistent symptoms or thrombus propagation despite medical treatment. [1] The key immediate objective is to prevent extension into the deep system and identify any concurrent DVT. [1][14]" ], "bullets": [] } ], "table": { "caption": "Treatment selection for lower-extremity superficial venous thrombosis. [1][14][16][20]", "columns": [ "Clinical pattern", "Preferred management", "Important limitation or escalation trigger" ], "rows": [ [ "Limited below-knee SVT; no DVT; no major progression-risk features", "NSAID plus compression for symptom control. [1]", "Reassess if symptoms worsen or the cord extends proximally. [1]" ], [ "SVT at least 5 cm or proximal to knee, with no DVT", "Fondaparinux 2.5 mg SC daily for 45 days. [14][16]", "Rivaroxaban 10 mg daily is a comparative oral option in patients with additional risk factors. [3][16]" ], [ "Prior VTE/SVT, active cancer, recent surgery, severe symptoms, or great saphenous involvement", "Favor anticoagulation if bleeding risk permits. [14][16]", "Assess for concurrent DVT and anatomic extension on ultrasound. [14][17]" ], [ "Near saphenofemoral or saphenopopliteal junction", "Urgent anticoagulation-focused management; surgical ligation may be considered. [1][16]", "Exclude DVT and seek vascular/thrombosis input for propagation or persistent symptoms. [1]" ] ] } }, { "id": "conservative-treatment-and-follow-up", "eyebrow": "Lower-Risk Disease", "heading": "When NSAIDs and compression are sufficient", "intro": "Conservative treatment is appropriate only after imaging excludes deep venous involvement and anatomy is low risk.", "paragraphs": [ "Manage limited below-knee SVT without DVT using an NSAID and compression when there are no high-risk anatomic or clinical features. [1] NSAIDs reduce SVT extension in trial evidence, but fondaparinux—not NSAIDs—reduced symptomatic VTE compared with placebo in the summarized randomized evidence. [16] Explain this distinction when choosing symptom-directed treatment rather than anticoagulation.", "Compression and local symptom measures can reduce discomfort, but they should not delay ultrasound or replace anticoagulation when thrombus is extensive, proximal, or close to a deep-venous junction. [1][17] Repeat examination and reassess the treatment plan for increasing pain, expanding erythema, extension of a palpable cord, or new cardiopulmonary symptoms; thrombus propagation despite medical treatment is a reason to consider surgery or anticoagulation escalation. [1]" ], "bullets": [ "Use conservative therapy only after DVT has been excluded and low-risk anatomy is established. [1][14]", "Give explicit return precautions for new dyspnea, chest pain, syncope, worsening leg swelling, or proximal progression of the cord.", "Re-image or escalate management for suspected propagation rather than attributing persistent progression to uncomplicated inflammation. [1][8]" ], "subsections": [], "table": null }, { "id": "secondary-causes-and-special-situations", "eyebrow": "Etiologic Branches", "heading": "When SVT should trigger evaluation beyond the leg", "intro": "Pattern recognition should guide selective evaluation rather than indiscriminate thrombophilia testing.", "paragraphs": [ "Do not routinely investigate every patient with SVT for inherited thrombophilia or occult malignancy. [14] Instead, identify whether the event is recurrent, unprovoked, migratory, bilateral, or occurring without varicose veins, because these patterns increase concern for systemic thrombotic drivers and should also prompt meticulous evaluation for DVT and PE. [7][9][24]", "Migratory thrombophlebitis warrants investigation for visceral malignancy. [14][24] This pattern consists of recurrent superficial inflammatory-thrombotic lesions at changing sites and may represent Trousseau syndrome from tumor-driven hypercoagulability. [24] In this setting, pursue an age- and risk-appropriate malignancy evaluation rather than treating repeated episodes as isolated local venous inflammation.", "Consider septic thrombophlebitis when local venous thrombosis is accompanied by systemic infectious features or concern for purulence. Septic disease includes infection of the thrombus and can involve purulent intraluminal material, vein necrosis, and periphlebitic abscess; evaluation incorporates examination, blood studies, and duplex ultrasonography. [8] This pattern requires infection-directed management rather than NSAID-only treatment.", "Upper-extremity SVT is less likely than lower-extremity SVT to progress to DVT, but ultrasound remains useful when thrombus extent or deep-system involvement is uncertain. [8] Pregnancy is a progression-risk feature in SVT, and postpartum occurrence is notable; involve obstetric and thrombosis expertise when anticoagulant selection is needed. [13][16]" ], "bullets": [ "Migratory or recurrent SVT: evaluate for visceral malignancy. [14][24]", "Fever, suspected purulence, or systemic illness: evaluate for septic thrombophlebitis with blood studies and duplex ultrasound. [8]", "Unprovoked SVT without varicosities: maintain a lower threshold for DVT/PE assessment and systemic risk review. [7][9]", "Pregnancy or postpartum SVT: classify as higher progression risk and coordinate anticoagulant management with obstetric care. [13][16]" ], "subsections": [], "table": { "caption": "Patterns that should redirect the SVT workup. [8][14][24]", "columns": [ "Pattern", "Concern", "Immediate diagnostic direction" ], "rows": [ [ "Migratory, recurrent superficial cords at changing sites", "Cancer-associated migratory thrombophlebitis. [14][24]", "Evaluate for visceral malignancy. [14]" ], [ "Fever, purulent local process, or systemic infectious features", "Septic thrombophlebitis with infected thrombus. [8]", "Perform examination, blood studies, and duplex ultrasonography. [8]" ], [ "Proximal extension toward deep-vein junction", "Deep-system propagation and DVT. [1][16]", "Urgent duplex assessment and anticoagulation-focused management. [1][16]" ], [ "New chest symptoms or hemodynamic compromise", "Pulmonary embolism. [1][13]", "Evaluate as suspected PE rather than isolated SVT." ] ] } } ], "faq": [], "references": [ { "number": 1, "title": "Superficial thrombophlebitis (superficial venous thrombosis) | The BMJ", "detail": "www.bmj.com", "url": "https://www.bmj.com/content/350/bmj.h2039.short", "authors": "www.bmj.com", "host": "www.bmj.com" }, { "number": 2, "title": "Re: Superficial thrombophlebitis (superficial venous thrombosis) | The BMJ", "detail": "www.bmj.com", "url": "https://www.bmj.com/content/350/bmj.h2039/rr", "authors": "www.bmj.com", "host": "www.bmj.com" }, { "number": 3, "title": "the open-label, randomised, non-inferiority SURPRISE phase 3b trial", "detail": "www.thelancet.com", "url": "https://www.thelancet.com/article/S2352-3026(17)30014-5/abstract", "authors": "www.thelancet.com", "host": "www.thelancet.com" }, { "number": 4, "title": "Direct oral anticoagulants for superficial-vein thrombosis - The Lancet", "detail": "www.thelancet.com", "url": "https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30013-3/abstract", "authors": "www.thelancet.com", "host": "www.thelancet.com" }, { "number": 5, "title": "Review: Fondaparinux reduces VTE and recurrence in superficial ...", "detail": "www.acpjournals.org", "url": "https://www.acpjournals.org/doi/10.7326/0003-4819-157-4-201208210-02004", "authors": "www.acpjournals.org", "host": "www.acpjournals.org" }, { "number": 6, "title": "Ultrasound in Superficial Thrombophlebitis:... : Journal of Emergencies, Trauma, and Shock", "detail": "journals.lww.com", "url": "https://journals.lww.com/onlinejets/fulltext/2026/04000/ultrasound_in_superficial_thrombophlebitis_.7.aspx", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 7, "title": "Vein Superficial Thrombosis - an overview", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/vein-superficial-thrombosis", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 8, "title": "Septic Thrombophlebitis - an overview", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/topics/medicine-and-dentistry/septic-thrombophlebitis", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 9, "title": "Superficial Vein Thrombosis - an overview | ScienceDirect Topics", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/superficial-vein-thrombosis", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 10, "title": "Early Endovenous Thermal Ablation With Concomitant ...", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S2666688X26000195", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com" }, { "number": 11, "title": "Is anticoagulation appropriate for the treatment... - Ovid", "detail": "journals.lww.com", "url": "https://journals.lww.com/ebp/fulltext/2022/03000/is_anticoagulation_appropriate_for_the_treatment.14.aspx", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 12, "title": "What is the best management and treatment for... : Evidence-Based Practice", "detail": "journals.lww.com", "url": "https://journals.lww.com/ebp/fulltext/2012/02000/what_is_the_best_management_and_treatment_for.14.aspx", "authors": "journals.lww.com", "host": "journals.lww.com" }, { "number": 13, "title": "Superficial Thrombophlebitis - StatPearls - NCBI Bookshelf", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=69bfe090ad376021bfd95c3b", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 14, "title": "Superficial Vein Thrombosis - StatPearls - NCBI Bookshelf", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/sites/books/n/statpearls/article-30109", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 15, "title": "Superficial Vein Thrombosis - StatPearls - NCBI Bookshelf - NIH", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK556017", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" }, { "number": 16, "title": "Superficial Thrombophlebitis: The Less Dangerous Cousin of Deep Vein Thrombosis That Can Still Cause Harm | The Hematologist | American Society of Hematology", "detail": "ashpublications.org", "url": "https://ashpublications.org/thehematologist/article/doi/10.1182/hem.V16.4.9643/463201/Superficial-Thrombophlebitis-The-Less-Dangerous", "authors": "ashpublications.org", "host": "ashpublications.org" }, { "number": 17, "title": "Treatment of Superficial Vein Thrombosis: Recent Advances, Unmet ...", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11312049", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 18, "title": "Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9680918", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 19, "title": "Swollen lower limb—1: General assessment and deep vein ... - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC1127644", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 20, "title": "Scenario: Management of superficial vein thrombosis - CKS - NICE", "detail": "cks.nice.org.uk", "url": "https://cks.nice.org.uk/topics/superficial-vein-thrombosis-superficial-thrombophlebitis/management/management-of-superficial-vein-thrombosis", "authors": "cks.nice.org.uk", "host": "cks.nice.org.uk" }, { "number": 21, "title": "Fondaparinux for Isolated Superficial Vein Thrombosis of the Legs", "detail": "journal.chestnet.org", "url": "https://journal.chestnet.org/article/S0012-3692(12)60068-3/abstract", "authors": "journal.chestnet.org", "host": "journal.chestnet.org" }, { "number": 22, "title": "Superficial vein thrombosis (superficial thrombophlebitis) - CKS - NICE", "detail": "cks.nice.org.uk", "url": "https://cks.nice.org.uk/topics/superficial-vein-thrombosis-superficial-thrombophlebitis", "authors": "cks.nice.org.uk", "host": "cks.nice.org.uk" }, { "number": 23, "title": "Management and outcomes of superficial vein thrombosis: a single-center retrospective study", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10770555", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov" }, { "number": 24, "title": "Migratory Thrombophlebitis - StatPearls - NCBI Bookshelf", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK547702", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov" } ], "editorialNote": "Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.", "citations": [ { "number": 1, "title": "Superficial thrombophlebitis (superficial venous thrombosis) | The BMJ", "detail": "www.bmj.com", "url": "https://www.bmj.com/content/350/bmj.h2039.short", "authors": "www.bmj.com", "host": "www.bmj.com", "snippet": "Title: Superficial thrombophlebitis (superficial venous thrombosis) | The BMJ\n3. Superficial thrombophlebitis (superficial venous thrombosis). # Superficial thrombophlebitis (superficial venous thrombosis). Cite this as: BMJ 2015;350:h2039. 2. J M Scriven, consultant vascular surgeon. 1. 1Department", "score": 0.61972505 }, { "number": 2, "title": "Re: Superficial thrombophlebitis (superficial venous thrombosis) | The BMJ", "detail": "www.bmj.com", "url": "https://www.bmj.com/content/350/bmj.h2039/rr", "authors": "www.bmj.com", "host": "www.bmj.com", "snippet": "Intended for healthcare professionals\n\n## Search form\n\nRapid response to:\n\n# Superficial thrombophlebitis (superficial venous thrombosis)\n\n## Rapid Response:\n\n### Re: Superficial thrombophlebitis (superficial venous thrombosis)\n\n### \n\nNasr and Scriven include oestrogen based hormone therapy (HT) as ", "score": 0.42892754 }, { "number": 3, "title": "the open-label, randomised, non-inferiority SURPRISE phase 3b trial", "detail": "www.thelancet.com", "url": "https://www.thelancet.com/article/S2352-3026(17)30014-5/abstract", "authors": "www.thelancet.com", "host": "www.thelancet.com", "snippet": "We compared efficacy outcomes in patients with superficial-vein thrombosis and additional risk factors given either rivaroxaban or fondaparinux", "score": 0.5155961 }, { "number": 4, "title": "Direct oral anticoagulants for superficial-vein thrombosis - The Lancet", "detail": "www.thelancet.com", "url": "https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(17)30013-3/abstract", "authors": "www.thelancet.com", "host": "www.thelancet.com", "snippet": "Following the results of this study, this regimen of fondaparinux was suggested by clinical guidelines for patients with superficial vein thrombosis of at least", "score": 0.4718322 }, { "number": 5, "title": "Review: Fondaparinux reduces VTE and recurrence in superficial ...", "detail": "www.acpjournals.org", "url": "https://www.acpjournals.org/doi/10.7326/0003-4819-157-4-201208210-02004", "authors": "www.acpjournals.org", "host": "www.acpjournals.org", "snippet": "In patients with superficial thrombophlebitis of the leg, prophylactic doses of fondaparinux reduce venous thromboembolism and extension or recurrence of", "score": 0.56258565 }, { "number": 6, "title": "Ultrasound in Superficial Thrombophlebitis:... : Journal of Emergencies, Trauma, and Shock", "detail": "journals.lww.com", "url": "https://journals.lww.com/onlinejets/fulltext/2026/04000/ultrasound_in_superficial_thrombophlebitis_.7.aspx", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Title: Ultrasound in Superficial Thrombophlebitis:... : Journal of Emergencies, Trauma, and Shock\nJournal of Emergencies, Trauma, and Shock. Image 3: Crossmark: Check for updates. # Ultrasound in Superficial Thrombophlebitis: Clarifying Undifferentiated Leg Pain and Erythema. Journal of Emergencies,", "score": 0.40627348 }, { "number": 7, "title": "Vein Superficial Thrombosis - an overview", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/vein-superficial-thrombosis", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Diagnosis of DVT may require duplex venous ultrasonography (two-dimensional imaging, pulse wave Doppler interrogation). Doppler ultrasound measures the velocity of blood flow in veins. Impedence plethysmography measures changes in venous capacitance (valsalva). Imaging using MRI and venography are o", "score": 0.6108487 }, { "number": 8, "title": "Septic Thrombophlebitis - an overview", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/topics/medicine-and-dentistry/septic-thrombophlebitis", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Duplex ultrasonography is helpful in diagnosing a SVT. This test is inexpensive, noninvasive, and reliable for determining the location and extent of thrombotic disease. Duplex ultrasound findings in SVT can include surrounding soft tissue edema, vein wall thickening, and increased echogenicity. The", "score": 0.5925965 }, { "number": 9, "title": "Superficial Vein Thrombosis - an overview | ScienceDirect Topics", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/superficial-vein-thrombosis", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Diagnosis of DVT may require duplex venous ultrasonography (two-dimensional imaging, pulse wave Doppler interrogation). Doppler ultrasound measures the velocity of blood flow in veins. Impedence plethysmography measures changes in venous capacitance (valsalva). Imaging using MRI and venography are o", "score": 0.5852203 }, { "number": 10, "title": "Early Endovenous Thermal Ablation With Concomitant ...", "detail": "www.sciencedirect.com", "url": "https://www.sciencedirect.com/science/article/pii/S2666688X26000195", "authors": "www.sciencedirect.com", "host": "www.sciencedirect.com", "snippet": "Patient selection Inclusion criteria required patients to have an acute presentation of lower extremity superficial thrombosis … duplex ultrasound confirmation", "score": 0.52027756 }, { "number": 11, "title": "Is anticoagulation appropriate for the treatment... - Ovid", "detail": "journals.lww.com", "url": "https://journals.lww.com/ebp/fulltext/2022/03000/is_anticoagulation_appropriate_for_the_treatment.14.aspx", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "Fondaparinux has the lowest rate of pulmonary embolism/deep vein thrombosis and superficial vein thrombosis (SVT) recurrence. Rivaroxaban is noninferior to", "score": 0.43900222 }, { "number": 12, "title": "What is the best management and treatment for... : Evidence-Based Practice", "detail": "journals.lww.com", "url": "https://journals.lww.com/ebp/fulltext/2012/02000/what_is_the_best_management_and_treatment_for.14.aspx", "authors": "journals.lww.com", "host": "journals.lww.com", "snippet": "# What is the best management and treatment for recurrent superficial vein thrombosis of the lower extremity?\n\n## Evidence-Based Answer\n\nProphylactic- and treatment-dose low-molecular-weight heparin (LMWH), nonsteroidal anti-inflammatory drugs (NSAIDs), and venous stripping with subsequent use of el", "score": 0.3438268 }, { "number": 13, "title": "Superficial Thrombophlebitis - StatPearls - NCBI Bookshelf", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=69bfe090ad376021bfd95c3b", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "Title: Superficial Thrombophlebitis - StatPearls - NCBI Bookshelf\n# Superficial Thrombophlebitis. Superficial thrombophlebitis, increasingly known as superficial venous thrombosis, is no longer considered benign. It is often associated with concomitant deep venous thrombosis or pulmonary embolism, p", "score": 0.85825616 }, { "number": 14, "title": "Superficial Vein Thrombosis - StatPearls - NCBI Bookshelf", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/sites/books/n/statpearls/article-30109", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "## StatPearls [Internet].\n\n# Superficial Vein Thrombosis\n\nAugusta Czysz; Sheetal L. Higbee.\n\nLast Update: January 2, 2023.\n\n## Continuing Education Activity\n\nSuperficial thrombophlebitis, increasingly known as superficial venous thrombosis, is no longer considered benign. It is often associated with", "score": 0.7485182 }, { "number": 15, "title": "Superficial Vein Thrombosis - StatPearls - NCBI Bookshelf - NIH", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK556017", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "## Continuing Education Activity\n\nSuperficial thrombophlebitis, increasingly known as superficial venous thrombosis, is no longer considered benign. It is often associated with concomitant deep venous thrombosis or pulmonary embolism, potentially due to a more sinister underlying issue. As such, the", "score": 0.6836946 }, { "number": 16, "title": "Superficial Thrombophlebitis: The Less Dangerous Cousin of Deep Vein Thrombosis That Can Still Cause Harm | The Hematologist | American Society of Hematology", "detail": "ashpublications.org", "url": "https://ashpublications.org/thehematologist/article/doi/10.1182/hem.V16.4.9643/463201/Superficial-Thrombophlebitis-The-Less-Dangerous", "authors": "ashpublications.org", "host": "ashpublications.org", "snippet": "Title: Superficial Thrombophlebitis: The Less Dangerous Cousin of Deep Vein Thrombosis That Can Still Cause Harm | The Hematologist | American Society of Hematology\n# Superficial Thrombophlebitis: The Less Dangerous Cousin of Deep Vein Thrombosis That Can Still Cause Harm *Free*. Lori-Ann Linkins; S", "score": 0.6636041 }, { "number": 17, "title": "Treatment of Superficial Vein Thrombosis: Recent Advances, Unmet ...", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11312049", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "A systematic review and meta-analysis of randomized controlled trials involving 7296 patients with lower extremity SVT summarized the efficacy and safety of topical, surgical, and medical treatments for SVT . Treatment modalities included anticoagulation with low molecular weight heparin (LMWH), unf", "score": 0.65146625 }, { "number": 18, "title": "Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9680918", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "OR dalteparina OR edoxaban OR apixaban OR betrixaban) | Sep 2020: 6 Nov 2021: 2 | [...] History of DVT or PE\n\nDocumented clotting/coagulation disorders\n\nCancer treatment within previous year\n\nHistory of venous stasis or superficial thrombophlebitis\n\nVein stripping or ligation\n\nObesity hypoventilatio", "score": 0.2972766 }, { "number": 19, "title": "Swollen lower limb—1: General assessment and deep vein ... - PMC", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC1127644", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "Ongoing risk—for example, malignancy: 6 -12 months\n\n Recurrent pulmonary embolism or deep vein thrombosis: 6-12 months\n\n Patients with high risk of recurrent thrombosis exceeding risk of anticoagulation: indefinite duration (subject to review)\n\n## can be treated with subcutaneous low molecular ", "score": 0.21055557 }, { "number": 20, "title": "Scenario: Management of superficial vein thrombosis - CKS - NICE", "detail": "cks.nice.org.uk", "url": "https://cks.nice.org.uk/topics/superficial-vein-thrombosis-superficial-thrombophlebitis/management/management-of-superficial-vein-thrombosis", "authors": "cks.nice.org.uk", "host": "cks.nice.org.uk", "snippet": "... treatment with prophylactic doses of low molecular weight heparin (LMWH) for 30 days (off-label indication) or fondaparinux for 30–45 days [Tait, 2012].", "score": 0.6654328 }, { "number": 21, "title": "Fondaparinux for Isolated Superficial Vein Thrombosis of the Legs", "detail": "journal.chestnet.org", "url": "https://journal.chestnet.org/article/S0012-3692(12)60068-3/abstract", "authors": "journal.chestnet.org", "host": "journal.chestnet.org", "snippet": "Fondaparinux for 45 days does not appear to be cost-effective when treating patients with isolated SVT of the legs. A better value for money could be obtained", "score": 0.4851368 }, { "number": 22, "title": "Superficial vein thrombosis (superficial thrombophlebitis) - CKS - NICE", "detail": "cks.nice.org.uk", "url": "https://cks.nice.org.uk/topics/superficial-vein-thrombosis-superficial-thrombophlebitis", "authors": "cks.nice.org.uk", "host": "cks.nice.org.uk", "snippet": "Superficial thrombophlebitis is a common disorder that occurs when a superficial vein becomes inflamed (phlebitis) and the blood within it clots.", "score": 0.41307515 }, { "number": 23, "title": "Management and outcomes of superficial vein thrombosis: a single-center retrospective study", "detail": "pmc.ncbi.nlm.nih.gov", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10770555", "authors": "pmc.ncbi.nlm.nih.gov", "host": "pmc.ncbi.nlm.nih.gov", "snippet": "associated with an elevated risk of VTE . We also report a significantly higher overall complication rate in our cohort compared to the rates reported in previous clinical trials (29.2% vs 0.9%-5.9%) ( ( ( ( In the CALISTO and SURPRISE studies using low-dose anticoagulant therapy, the primary effica", "score": 0.7011614 }, { "number": 24, "title": "Migratory Thrombophlebitis - StatPearls - NCBI Bookshelf", "detail": "www.ncbi.nlm.nih.gov", "url": "https://www.ncbi.nlm.nih.gov/books/NBK547702", "authors": "www.ncbi.nlm.nih.gov", "host": "www.ncbi.nlm.nih.gov", "snippet": "Migratory thrombophlebitis is a recurrent inflammatory and thrombotic condition of superficial veins that may signal underlying systemic disease, including malignancy. When associated with cancer, it is termed Trousseau syndrome and reflects tumor-driven hypercoagulability. Clinical presentation ran", "score": 0.49963441 } ], "publishedAt": "2026-09-15T23:00:14.516744+00:00", "updatedAt": "2026-09-15T23:00:14.516744+00:00", "readingMinutes": 6, "slug": "superficial-thrombophlebitis" }